Xilio Therapeutics (XLO) Enterprise Value (2020 - 2026)

Xilio Therapeutics has disclosed Enterprise Value across 7 years of filings, most recently posting -$150.3 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$150.3 million, down 68.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$150.3 million (down 68.74% YoY), and the FY2025 annual result was -$137.5 million, down 148.74% from the prior year.
• Enterprise Value came in at -$150.3 million for Q1 2026 at Xilio Therapeutics, down from -$137.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$34.0 million in Q1 2024 to a low of -$177.0 million in Q1 2022.
• The 5-year median for Enterprise Value is -$93.3 million (2023), against an average of -$99.8 million.
• Across the five-year window, Enterprise Value surged 63.57% in 2024 and plunged 162.13% in 2025, its largest moves.
• Xilio Therapeutics' Enterprise Value stood at -$120.4 million in 2022, then surged by 62.87% to -$44.7 million in 2023, then declined by 23.68% to -$55.3 million in 2024, then slumped by 148.74% to -$137.5 million in 2025, then decreased by 9.28% to -$150.3 million in 2026.
• The last three Enterprise Value figures came in at -$150.3 million (Q1 2026), -$137.5 million (Q4 2025), and -$103.8 million (Q3 2025), per Business Quant data.